Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 13/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179882 | 0.86 | NMT1 (0.37) | NMT1 | |
| SCHEMBL391222 | 0.84 | F2RL3 (0.34) | NMT1 | |
| SCHEMBL389716 | 0.79 | GPR119 (0.48) | — | |
| SCHEMBL391223 | 0.77 | NMT1 (0.34) | NMT1 | |
| SCHEMBL5133750 | 0.75 | NMT1 (0.36) | NMT1 | |
| SCHEMBL13186626 | 0.72 | NMT1 (0.40) | NMT1 | |
| SCHEMBL5133696 | 0.72 | GPR119 (0.33) | — | |
| SCHEMBL4163141 | 0.71 | CHEK1 (0.34) | NMT1 | |
| SCHEMBL4521480 | 0.71 | ALDH1A1 (0.43) | NMT1 | |
| SCHEMBL392191 | 0.70 | GPR119 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1838706-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067532-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | GPR119, GPR65, GPR84 | NMT1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.